John Oyler Sells 11,698 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 11,698 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $298.34, for a total value of $3,489,981.32. Following the sale, the chief executive officer owned 11,698 shares in the company, valued at approximately $3,489,981.32. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total value of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $311.26 on Thursday. The stock’s fifty day moving average is $290.20 and its two-hundred day moving average is $308.90. The company has a market capitalization of $34.15 billion, a PE ratio of 69.63 and a beta of 0.49. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $253.95 and a 52 week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ONC shares. Guggenheim raised their price objective on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Royal Bank Of Canada raised their price target on BeOne Medicines from $436.00 to $451.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Citizens Jmp restated a “market outperform” rating and issued a $396.00 price objective on shares of BeOne Medicines in a report on Wednesday, July 1st. Barclays lowered their price objective on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Wall Street Zen downgraded shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $390.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. EFG International AG bought a new position in shares of BeOne Medicines in the 4th quarter worth $25,000. Leonteq Securities AG bought a new stake in BeOne Medicines during the fourth quarter valued at about $35,000. Daiwa Securities Group Inc. bought a new stake in BeOne Medicines during the second quarter valued at about $35,000. CWM LLC grew its stake in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new position in BeOne Medicines in the fourth quarter valued at about $61,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.